Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2018

View Archived Issues

FDA expands approval of Gilotrif in NSCLC

SAAP-148 shows promise for combating multidrug-resistant bacteria

Prolong Pharmaceuticals gives update on ongoing projects

FDA approves of Trisenox injection for first-line treatment of acute promyelocytic leukemia

Eurocine Vaccines cleared to begin study of Immunose Flu

InflaRx presents company and pipeline overview

Nanoparticle-encapsulated rapamycin induces immune tolerance to restore immunotoxin activity

FDA grants orphan drug designation to BB-301 for oculopharyngeal muscular dystrophy

FDA accepts Sandoz's BLA for adalimumab biosimilar

LIDDS raises capital through direct share issue

Suzhou Kintor Pharmaceuticals patents mTOR and/or PI3K inhibitors

Japanese approval sought for Opdivo with Yervoy for unresectable or metastatic renal cell carcinoma

Aprinoia Therapeutics completes series B financing round

ValiRx reports phase II data on VAL-401 in late-stage NSCLC

Universite Jagellonne and Neurolixis divulge 5-HT1A receptor agonists

Janssen identifies novel TLR7 and/or TLR8 agonists

Y-mAbs commences phase III study of naxitamab in neuroblastoma with osteomedullary disease

LifeArc presents novel antivirals for HFMD

Novel HLA-G-targeting antibodies presented by Invectys

NHLBI initiates phase I study of HERV-E TCR transduced autologous T cells in renal cell carcinoma

MedImmune studies MEDI-5884 in stable coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...